-
Je něco špatně v tomto záznamu ?
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
AM. Newman, M. Zaka, P. Zhou, AE. Blain, A. Erhorn, A. Barnard, RE. Crossland, S. Wilkinson, A. Enshaei, J. De Zordi, F. Harding, M. Taj, KM. Wood, D. Televantou, SD. Turner, GAA. Burke, CJ. Harrison, S. Bomken, CM. Bacon, V. Rand
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
MR/S021590/1
Medical Research Council - United Kingdom
Department of Health - United Kingdom
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- B-buněčný lymfom genetika patologie MeSH
- dítě MeSH
- genetické lokusy MeSH
- genová dávka MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mutace MeSH
- nádorový supresorový protein p53 genetika MeSH
- předškolní dítě MeSH
- progrese nemoci MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.
CEITEC Masaryk University Brno Czech Republic
Department of Paediatric Oncology Royal Marsden Hospital Sutton Surrey UK
National Horizons Centre Teesside University 38 John Dixon Lane Darlington UK
School of Health and Life Sciences Teesside University Middlesbrough UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010892
- 003
- CZ-PrNML
- 005
- 20220506130104.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-021-01444-6 $2 doi
- 035 __
- $a (PubMed)34675373
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Newman, Alexander M $u School of Health & Life Sciences, Teesside University, Middlesbrough, UK $u National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington, UK $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 245 10
- $a Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma / $c AM. Newman, M. Zaka, P. Zhou, AE. Blain, A. Erhorn, A. Barnard, RE. Crossland, S. Wilkinson, A. Enshaei, J. De Zordi, F. Harding, M. Taj, KM. Wood, D. Televantou, SD. Turner, GAA. Burke, CJ. Harrison, S. Bomken, CM. Bacon, V. Rand
- 520 9_
- $a Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genová dávka $7 D018628
- 650 _2
- $a genetické lokusy $7 D056426
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a B-buněčný lymfom $x genetika $x patologie $7 D016393
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zaka, Masood $u School of Health & Life Sciences, Teesside University, Middlesbrough, UK $u National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington, UK $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Zhou, Peixun $u School of Health & Life Sciences, Teesside University, Middlesbrough, UK $u National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington, UK $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Blain, Alex E $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $1 https://orcid.org/000000018045822X
- 700 1_
- $a Erhorn, Amy $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Barnard, Amy $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Crossland, Rachel E $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Wilkinson, Sarah $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Enshaei, Amir $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a De Zordi, Julian $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Harding, Fiona $u Newcastle Genetics Laboratory, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Taj, Mary $u Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey, UK
- 700 1_
- $a Wood, Katrina M $u Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Televantou, Despina $u Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK $u CEITEC, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000284394507
- 700 1_
- $a Burke, G A Amos $u Department of Paediatric Haematology, Oncology and Palliative Care, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK $1 https://orcid.org/0000000326719972
- 700 1_
- $a Harrison, Christine J $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Bomken, Simon $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $u Department of Paediatric and Adolescent Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Bacon, Chris M $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $u Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Rand, Vikki $u School of Health & Life Sciences, Teesside University, Middlesbrough, UK. v.rand@tees.ac.uk $u National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington, UK. v.rand@tees.ac.uk $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. v.rand@tees.ac.uk $1 https://orcid.org/0000000221988949
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 36, č. 3 (2022), s. 781-789
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34675373 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130056 $b ABA008
- 999 __
- $a ok $b bmc $g 1788826 $s 1162090
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 36 $c 3 $d 781-789 $e 20211021 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- GRA __
- $a MR/S021590/1 $p Medical Research Council $2 United Kingdom
- GRA __
- $p Department of Health $2 United Kingdom
- LZP __
- $a Pubmed-20220425
